Rhenium (186Re) obisbemeda by Plus Therapeutics for Head And Neck Cancer: Likelihood of Approval

Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Head And Neck Cancer.…